Merck & Co., Inc. (mrk)
MRK Valuation
| P/E (trailing) | 120.39 |
| P/E (forward) | 15.53 |
| EV/EBITDA | 14.28 |
| Price/Sales | 5.49 |
| Price/Book | 8.72 |
| Market cap | $365.34B |
Start Free — open MRK in Vest Terminal
Access live data, filings, ownership, and analysis for Merck & Co., Inc..
Merck & Co., Inc. FAQ
What does Merck & Co., Inc. (MRK) do?
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerb…
What is MRK's P/E ratio?
Merck & Co., Inc. has a trailing P/E of 120.39× based on publicly available market data.
Does MRK pay a dividend?
Indicated dividend yield: 2.2%. Confirm ex-dates and payout history in Vest Terminal.
What sector is MRK in?
Merck & Co., Inc. is classified in Healthcare (Drug Manufacturers - General) on NYQ.
What is MRK's market capitalization?
Approximate market cap: $365.34B.
What are the main risks for MRK?
Key risks include elevated valuation, among factors on this page.
What are the strengths of MRK?
Potential positives include revenue growth of 5.1% year-over-year, gross margin of 75.9% supports competitive unit economics.
Where can I get analyst estimates for MRK?
Public analyst price targets and consensus for Merck & Co., Inc. are on the free /stocks/mrk/estimates page. Deeper estimate history and models are available in Vest Terminal.